12
Participants
Start Date
April 30, 2013
Primary Completion Date
November 30, 2013
Study Completion Date
March 31, 2015
Brentuximab vedotin
1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
ABVD
Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
"Institute of Hematology and Medical Oncology L. e A. Seràgnoli at the University of Bologna", Bologna
Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena
Hematology, Azienda Ospedaliera Arcispedale S.Maria Nuova IRCCS, Reggio Emilia
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
University of Modena and Reggio Emilia
OTHER